© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
Experts provide an overview on the management of inflammatory bowel disease using biologics and discussing their safety and efficacy data presented at the DDW Virtual 2021.
August 19th 2021
Expert gastroenterologists review the pathophysiology of inflammatory bowel disease (IBD) along with the associated risk factors.
Effect of age, gender, racial, and socioeconomic disparities on the incidence and prevalence of inflammatory bowel disease (IBD).
August 26th 2021
Expert opinions on the effect of the progressive, relapsing nature of inflammatory bowel disease on a patients’ quality of life.
Panel of gastroenterologists share their perspectives regarding the diagnostic work-up for patients who may have symptoms suggestive of IBD.
September 2nd 2021
A panel of experts discuss the latest guidelines and how they make a treatment decision for patients with ulcerative colitis and Crohn’s disease.
Important patient factors to consider other than severity of disease when choosing a therapeutic agent for inflammatory bowel disease.
September 9th 2021
Initial IBD therapy for a patient with low-risk disease and measuring treatment response on initial therapy.
September 10th 2021
Expert gastroenterologists share their perspectives regarding overall treatment approach in a patient with moderate- to high-risk inflammatory bowel disease.
September 16th 2021
Indications for surgery in treating patients for ulcerative colitis (UC) and Crohn disease.
A panel of experts share their experiences with the use of biologics for the treatment of inflammatory bowel diseases (IBDs).
Guselkumab Linked to Improved Psoriasis Treatment Continuation, Remission
The Signs and Symptoms of Stevens-Johnson Syndrome
Institutional Perspectives in Type 2 Diabetes: Contemporary Approaches to Insulin Treatment